I think we are safe. The roundtable appears to be discussing "Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer" (https://ascopubs.org/doi/full/10.1200/JCO.20.03420), which focuses on clinical progress. FTO is not mentioned anywhere in the report, likely as it is preclinical for everyone except Race.
I would think the wealth of work presented in the report would leave no time for discussion on an even greater body of preclinical pathways under investigation. I could be completely wrong however as this is way out of my wheelhouse.
Industry news, page-36
-
- There are more pages in this discussion • 2,356 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.69 | $1.57 | $387.6K | 237.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 807 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 2376 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |